Aditya ChaudhuriThe Women’s National Basketball Association (WNBA) has announced a multi-year partnership agreement with Perrigo Company, a leading provider of consumer self-care products.
The deal will see Perrigo’s Opill, the first-ever daily birth control pill made available without a prescription in the US, partner with the WNBA, with the partnership focusing on building confidence, strength, and health equity.
Opill will also serve as an Associate Partner of the 2024 WNBA Draft.
Additionally, the WNBA and Opill will carry out programmes to reach out to college students and educate them about Opill.
Colie Edison, WNBA Chief Growth Officer, commented:
“At the WNBA, we are committed to addressing issues that matter to the players, and expanding access to reproductive healthcare is one of those key issues. It’s great to be working with a partner whose values align and authentically integrates into the health equity work our players are dedicated to.“
Leila Bahbah, Perrigo US Women’s Health Brand Lead, said:
“Opill is changing the game in reproductive health, just like the WNBA’s game-changing role in sports and pop culture. Building upon our shared commitment to foster equitable access and to increase health education, the goal of this partnership is to prioritise dialogue and resources in support of women’s reproductive health.“
